Oruka Therapeutics (ORKA)
NASDAQ:ORKA
ORKA Stock Chart & Stats
$44.48
-$0.35(-1.84%)
At close: 4:00 PM EST
$44.48
-$0.35(-1.84%)
Day’s Range― - ―
52-Week Range$5.49 - $47.25
Previous CloseN/A
Volume71.58K
Average Volume (3M)530.53K
Market Cap
$2.20B
Enterprise Value$1.62B
Total Cash (Recent Filing)$337.04M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 20, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding49,542,690
10 Day Avg. Volume602,310
30 Day Avg. Volume530,527
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-57.89K
Enterprise Value/Ebitda-14.71
Forecast
1Y Price Target
$61.50Price Target Upside38.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TimelineRapid enrollment and an accelerated schedule for reporting initial efficacy in the lead psoriasis program increases the likelihood of an earlier clinical readout that could materially re-rate the stock if results are positive.
Dosing Profile And ConvenienceA long half-life and the potential for infrequent subcutaneous dosing, including a possible once-yearly maintenance regimen, would offer a major convenience advantage that could drive physician and patient adoption versus current therapies.
Pipeline Expansion And Market OpportunityAdvancement of a second candidate into Phase 2 plus planned trials in hidradenitis suppurativa, together with dermatologist feedback indicating strong patient adoption potential, expands commercial upside if clinical results are favorable.
Bears Say
Cash Runway And Financing RiskCash resources appear limited relative to spending needs, raising the possibility of future financing that could dilute shareholders or delay development plans.
Limited Evidence BaseEfficacy claims are supported mainly by a small, single-center study, which limits confidence in upside until larger, randomized trials validate the findings.
Market Skepticism And Short InterestNotable short interest indicates market skepticism that could amplify downward pressure on the stock during clinical setbacks or capital-raising events.
Oruka Therapeutics News
ORKA FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Oruka Therapeutics lowest stock price was $5.49 and its highest was $47.25 in the past 12 months.
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $2.20B.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 53 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.636 by $0.186.
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate is -0.54.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 49,542,690 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went up 25.039%.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Currently, no hedge funds are holding shares in ORKA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oruka Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.50 (38.26% Upside)
$61.50 (38.26% Upside)
Hedge Fund Trend
Increased
By 523.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $112.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.61%
12-Months-Change
Fundamentals
Return on Equity
-25.30%
Trailing 12-Months
Asset Growth
23.38%
Trailing 12-Months
Company Description
Oruka Therapeutics
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
ORKA Stock 12 Month Forecast
Average Price Target
$61.50
▲(38.26% Upside)
Technical Analysis
Verastem
―
AnaptysBio
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―